KRON News and Press, Kronos Bio Inc. From 11/08/22

Earlier today, the company announced prioritization of clinical portfolio to focus on next-generation SYK inhibitor, lanraplenib and CDK9 inhibitor, KB-0742 $270.3 million in cash, cash equivalents and investments as of Sept. 30, 2022, with expected cash runway into Q2 2025 ...

Company to discontinue Phase 3 entospletinib trial for strategic reasons Enrollment continues for Phase 1/2b trial in relapsed/refractory AML with Kronos Bio’s next generation SYK inhibitor, lanraplenib Company on track to provide KB-0742 update from ongoing P...

SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present preclinical data in a poster at the EORTC-NCI-AACR Symposium on Molecula...

SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced participation in the H.C. Wainwright 24th Annual Global Investmen...

SAN MATEO, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that the first patient has been dosed in a Phase 1b/2 clinical trial of lanraplenib in combination with gilteritin...

Kronos Bio ( NASDAQ: KRON ) and Invivoscribe, a global provider of oncology diagnostic kits and services, on Tuesday said they had inked a deal to develop a companion diagnostic for use with investigational therapy entospletinib. KRON's entospletinib is the company's l...

Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML Canada NewsWire Companion diagnostic would be used following potential regulatory approval of entospletin...

On May 18, I wrote the first of three articles stating that healthcare stocks, and specifically biopharmaceuticals, had likely bottomed. XBI was at 68 and IBB 114. Both XBI and IBB have increased since then. I viewed the valuations a few months ago as being compelling in several insta...

The following slide deck was published by Kronos Bio, Inc. in conjunction with this event. For further details see: Kronos Bio (KRON) Investor Presentation - Slideshow

Kronos Bio press release ( NASDAQ: KRON ): Q2 GAAP EPS of -$0.59 beats by $0.10 . $292.4 million in cash, cash equivalents and investments as of June 30, 2022, providing expected cash runway into Q4 2024 For further details see: Kronos Bio  GAAP EPS ...